HOUSTON - The University of Texas M. D. Anderson Cancer Center will hold the first international inflammatory breast cancer (IBC) conference on December 6-7, to bring together internationally recognized breast cancer clinicians and scientists.
Participants will present new clinical discoveries and participate in educational workshops, with the goal of improving diagnosis and management of this rare but deadly disease.
During the conference, the new IBC International Consortium will be formalized to develop joint international projects aimed at raising global awareness, increasing education and seeking funding to study the disease. The Consortium will consist of participants from ten countries, including: Australia, Belgium, Egypt, France, Italy, Japan, Spain, Tunisia, the United Arab Emirates and the United Kingdom. Among its first projects, the Consortium plans to establish a database of IBC cases that will include a tissue and serum bank.
"We are assembling researchers from around the world who are passionate about advancing progress against this disease," says Massimo Cristofanilli, M.D., associate professor in M. D. Anderson's Department of Breast Medical Oncology and Director of the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic. "This is the first conference dedicated exclusively to exchanging knowledge and discussing the complexities of IBC. Our goal is to step up the pace of research and education - ultimately saving women's lives."
IBC is a rare, fast-growing and aggressive cancer. It can spread in just a few weeks, and is often mistaken for something other than breast cancer, such as a rash or infection. Survival for women with IBC can be impeded by delays in diagnosis, a lack of expertise in treating IBC and its resistance to treatment with standard chemotherapy. IBC represents up to two percent of all breast cancer cases diagnosed each year in the United States; its prevalence globally is u
|Contact: Laura Sussman|
University of Texas M. D. Anderson Cancer Center